Krystal Biotech Inc (KRYS)
177.41
-6.81
(-3.70%)
USD |
NASDAQ |
Nov 14, 16:00
177.41
0.00 (0.00%)
After-Hours: 20:00
Krystal Biotech Research and Development Expense (Quarterly): 13.51M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 13.51M |
| June 30, 2024 | 15.58M |
| March 31, 2024 | 10.96M |
| December 31, 2023 | 11.37M |
| September 30, 2023 | 10.63M |
| June 30, 2023 | 12.14M |
| March 31, 2023 | 12.29M |
| December 31, 2022 | 10.74M |
| September 30, 2022 | 11.52M |
| June 30, 2022 | 10.89M |
| March 31, 2022 | 9.314M |
| December 31, 2021 | 9.009M |
| September 30, 2021 | 6.08M |
| June 30, 2021 | 6.594M |
| March 31, 2021 | 6.201M |
| December 31, 2020 | 5.672M |
| September 30, 2020 | 5.10M |
| Date | Value |
|---|---|
| June 30, 2020 | 3.639M |
| March 31, 2020 | 3.525M |
| December 31, 2019 | 4.349M |
| September 30, 2019 | 3.885M |
| June 30, 2019 | 4.216M |
| March 31, 2019 | 3.167M |
| December 31, 2018 | 2.802M |
| September 30, 2018 | 1.914M |
| June 30, 2018 | 1.525M |
| March 31, 2018 | 1.52M |
| December 31, 2017 | 1.088M |
| September 30, 2017 | 1.355M |
| June 30, 2017 | 0.446M |
| March 31, 2017 | 0.319M |
| December 31, 2016 | 0.402M |
| September 30, 2016 | 0.241M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.525M
Minimum
Mar 2020
15.58M
Maximum
Jun 2024
8.956M
Average
9.972M
Median
Research and Development Expense (Quarterly) Benchmarks
| Bioventus Inc | 3.808M |
| ADMA Biologics Inc | 0.412M |
| Alnylam Pharmaceuticals Inc | 270.93M |
| Amicus Therapeutics Inc | 26.16M |
| Apellis Pharmaceuticals Inc | 88.57M |